^
Association details:
| Biomarker: | AXL expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC
Excerpt:
...Provision of suitable tumor tissue for the analysis of Axl kinase expression and PD-L1 expression. Suitable tumor tissue must consist of a minimum of newly acquired (fresh) tumor tissue sample (as a FFPE block), together with either further newly acquired tumor tissue (i.e. further FFPE block) or an archival tumor tissue sample (as a further FFPE block or further 10 unstained slides). See Section 5.3.13 for further details...
Trial ID:
Source:
Title:
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
Published date:
11/09/2020
Excerpt:
Of the 15 radiologically-evaluable patients in Cohort-B1, 1 PR was observed; 6/7 (86%) cAXL-positive patients (1 PR, 5 SD) achieved clinical benefit while none was observed in cAXL negative patients. mPFS was 4.7mo in cAXL-positive and 1.9mo in cAXL-negative patients.
Trial ID:
Source:
Title:
A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
Published date:
11/08/2019
Excerpt:
17 AXL-positive patients were radiologically evaluable, with 6 responses observed (35%), as opposed to 2 (15%) in the 13 radiologically evaluable AXL-negative patients. Of the 10 responders, 4 had a TPS <1% (2 AXL positive, 2 negative), 3 TPS 1-49% (2 AXL-positive, 1 unknown), 1 TPS >50% (1 AXL-positive); 2 did not have a PD-L1 status available (1 AXL-positive, 1 unknown)....Promising clinical activity has been seen, particularly in pts with AXL-positive disease and including patients with PD-L-negative tumours. Overall, bemcentinib in combination with pembrolizumab was well tolerated.
Trial ID:
